Anti-colorectal cancer gene detection combined drug

When it comes to colorectal cancer, it can be said that the largest number of cancers occurred in the last five years. According to statistics, 12.8 people die of colorectal cancer every day. In recent years, many celebrities have also suffered greatly, including former President Lee Teng-hui, artist He Hang and Hugh Lee, the founder of the screen acting class. At present, the new concept of colorectal cancer treatment is to choose drugs with both curative effect and safety through the results of genetic testing, which can improve the chances of cure.

Selecting drugs with both efficacy and safety through the results of genetic testing can benefit patients with colorectal cancer. In order to benefit patients with colorectal cancer, the medical insurance bureau officially put the target drug ibis? (cetuximab) is included in the first-line payment of medical insurance, so that patients can use targeted drugs early without worrying about medical expenses.

Now, in addition to reducing the medical burden of patients, pharmaceutical companies will also pay for all patients with metastatic colorectal cancer. Patients can not only further save medical expenses, but also choose appropriate personalized treatment through genetic testing, which is a great boon for patients and their families.

KRAS detection is a clinical detection tool to predict the efficacy of targeted drugs for colorectal cancer. Patients with no mutation in KRAS gene are suitable to use targeted drugs of epidermal growth factor inhibitors (such as Erbishu).

All large medical institutions provide such testing services. After consulting the attending physician, patients with colorectal cancer can have this simple and convenient genetic test. People can consult the hospital or Taiwan Province Colorectal Cancer Patients Association (Tel: 02-27 19-8555).